Ketamine-Assisted Mindfulness-Based Cognitive Therapy for Depression: A Pilot Study
NCT05950711
Active Not Recruiting
The purpose of this study is to assess the feasibility of combining IV ketamine, a rapid acting antidepressant, with a course of Mindfulness-Based Cognitive Therapy (MBCT), for the initial and maintenance treatment of depression.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/07/2025
Locations: Harding Hospital, Columbus, Ohio
Conditions: Major Depressive Disorder
Register for Updates
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
NCT03039192
Completed
The purpose of the study is to evaluate the efficacy of intranasal esketamine 84 milligram (mg) compared with intranasal placebo in addition to comprehensive standard of care in reducing the symptoms of Major Depressive Disorder (MDD), including suicidal ideation, in participants who are assessed to be at imminent risk for suicide, as measured by the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) total score at 24 hours post first dose.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
04/25/2025
Locations: The Ohio State University, Columbus, Ohio
Conditions: Depressive Disorder, Major
Register for Updates
Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide
NCT03185819
Completed
The purpose of this study is to assess the efficacy of a single (first) dose of 3 fixed doses of intranasal esketamine {28 milligram (mg), 56 mg, and 84 mg} compared with psychoactive placebo (oral midazolam) in rapidly reducing the symptoms of major depressive disorder (MDD) including suicidal ideation in participants 12 to less than 18 years of age who are assessed to be at imminent risk for suicide.
Gender:
ALL
Ages:
Between 9 years and 17 years
Trial Updated:
04/25/2025
Locations: University of Cincinnati Hospital, Cincinnati, Ohio +2 locations
Conditions: Depressive Disorder, Major
Register for Updates
A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
NCT04599855
Completed
The purpose of this study is to evaluate the efficacy of each individual dose of esketamine nasal spray, 56 milligram (mg) and 84 mg, compared with placebo nasal spray in improving depressive symptoms in participants with treatment resistant depression (TRD), as assessed by the change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from Day 1 (prerandomization) to the end of the 4 week double-blind treatment phase (Day 28).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Ohio State University, Columbus, Ohio +1 locations
Conditions: Depressive Disorder, Treatment-Resistant
Register for Updates
A Pilot Study: a Non-opioid Technique for Postoperative Adenoidectomy Pain Relief in Pediatric Patients
NCT03714919
Completed
This proposed study will assess analgesic efficacy of a multi-modal, non-opioid analgesic regimen for providing surgical analgesia in pediatric patients undergoing adenoidectomy and to assess recovery characteristics in the post-anesthesia care unit (PACU) and at home following surgery.
Gender:
ALL
Ages:
Between 4 years and 8 years
Trial Updated:
01/19/2021
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Adenoid Hypertrophy
Register for Updates
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
NCT00516503
Completed
RATIONALE: Baclofen-amitriptyline-ketamine (BAK) gel may lessen peripheral neuropathy caused by chemotherapy. It is not yet known whether BAK gel is more effective than a placebo in treating peripheral neuropathy caused by chemotherapy . PURPOSE: This randomized phase III trial is studying BAK gel to see how well it works compared with a placebo in treating peripheral neuropathy caused by chemotherapy in patients with cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2017
Locations: Mary Rutan Hospital, Bellefontaine, Ohio +42 locations
Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neurotoxicity, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Sedation During Muscle Biopsy in Patients With Duchenne Muscular Dystrophy
NCT01645098
Completed
This is an interventional study on Duchenne muscular dystrophy patients who will be receiving sedation for a muscle biopsy as part of another study.
Gender:
MALE
Ages:
All
Trial Updated:
02/25/2015
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Duchenne Muscular Dystrophy
Register for Updates
An Open Prospective Trial of IV Ketamine in Suicidal Adolescents
NCT02048423
Unknown
1. Investigate the safety and effectiveness of a single dose of IV Ketamine for adolescents with suicidal ideation and depression. It is hypothesize that Ketamine will be well tolerated and significantly reduce depressive symptoms and suicidal ideation. 2. Explore whether decision making as measured by the Iowa Gambling Task changes before and after Ketamine infusion. It is hypothesize that IV Ketamine infusion will significantly improve the decision making ability a measured by the Iowa Gamblin... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
01/27/2014
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Major Depressive Disorder
Register for Updates
Use of a Multimedia Presentation for Informed Consent
NCT01955070
Completed
This is a prospective cohort study in which the standard verbal informed consent process for ketamine sedation is compared to a multimedia informed consent process. The goals include determining if parents prefer a multimedia consent process and evaluating the effectiveness of multimedia consent process.
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
09/27/2013
Locations: Nationwide Childrens, Columbus, Ohio
Conditions: Improving Informed Consent Process
Register for Updates
Safety and Efficacy of Repeated Doses of PMI-150 (Intranasal Ketamine) in Acute Post-operative Pain Following Orthopedic Surgery
NCT00709436
Completed
The purpose of this research study is to evaluate the safety and analgesic efficacy of PMI-150 (intranasal ketamine) compared to placebo in patients with acute post-operative pain following orthopedic trauma, injury, or surgery.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
01/10/2012
Locations: The Ohio State University, Columbus, Ohio
Conditions: Pain, Postoperative
Register for Updates